Preventing SARS-CoV-2 infection by blocking a tissue serine protease | Zendy

Katherine C. Jankousky | Zendy; Jonathan Schultz | Zendy; Sam Windham | Zendy; Andrés F. HenaoMartínez | Zendy; Carlos FrancoParedes | Zendy; Leland Shapiro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Preventing SARS-CoV-2 infection by blocking a tissue serine protease

Author(s) -

Katherine C. Jankousky,

Jonathan Schultz,

Sam Windham,

Andrés F. HenaoMartínez,

Carlos FrancoParedes,

Leland Shapiro

Publication year - 2020

Publication title -

therapeutic advances in infectious disease

Language(s) - English

Resource type - Journals

eISSN - 2049-937X

pISSN - 2049-9361

DOI - 10.1177/2049936120933076

Subject(s) - serine protease , covid-19 , coronavirus , pandemic , virology , viral entry , biology , immunology , medicine , protease , disease , virus , infectious disease (medical specialty) , viral replication , pathology , enzyme , outbreak , biochemistry

Currently, there are no proven pharmacologic interventions to reduce the clinical impact and prevent complications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the cause of the ongoing Coronavirus Disease of 2019 (COVID-19) pandemic. Selecting specific pharmacological targets for the treatment of viral pathogens has traditionally relied in blockage of specific steps in their replicative lifecycle in human cells. However, an alternative approach is reducing the molecular cleavage of the viral surface spike protein of SARS-CoV-2 to prevent viral entry into epithelial cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research